1
|
Deh K, Zhang G, Park AH, Cunningham CH, Bragagnolo ND, Lyashchenko S, Ahmmed S, Leftin A, Coffee E, Hricak H, Miloushev V, Mayerhoefer M, Keshari KR. First in-human evaluation of [1- 13C]pyruvate in D 2O for hyperpolarized MRI of the brain: A safety and feasibility study. Magn Reson Med 2024; 91:2559-2567. [PMID: 38205934 PMCID: PMC11009889 DOI: 10.1002/mrm.30002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 12/15/2023] [Accepted: 12/20/2023] [Indexed: 01/12/2024]
Abstract
PURPOSE To investigate the safety and value of hyperpolarized (HP) MRI of [1-13C]pyruvate in healthy volunteers using deuterium oxide (D2O) as a solvent. METHODS Healthy volunteers (n = 5), were injected with HP [1-13C]pyruvate dissolved in D2O and imaged with a metabolite-specific 3D dual-echo dynamic EPI sequence at 3T at one site (Site 1). Volunteers were monitored following the procedure to assess safety. Image characteristics, including SNR, were compared to data acquired in a separate cohort using water as a solvent (n = 5) at another site (Site 2). The apparent spin-lattice relaxation time (T1) of [1-13C]pyruvate was determined both in vitro and in vivo from a mono-exponential fit to the image intensity at each time point of our dynamic data. RESULTS All volunteers completed the study safely and reported no adverse effects. The use of D2O increased the T1 of [1-13C]pyruvate from 66.5 ± 1.6 s to 92.1 ± 5.1 s in vitro, which resulted in an increase in signal by a factor of 1.46 ± 0.03 at the time of injection (90 s after dissolution). The use of D2O also increased the apparent relaxation time of [1-13C]pyruvate by a factor of 1.4 ± 0.2 in vivo. After adjusting for inter-site SNR differences, the use of D2O was shown to increase image SNR by a factor of 2.6 ± 0.2 in humans. CONCLUSIONS HP [1-13C]pyruvate in D2O is safe for human imaging and provides an increase in T1 and SNR that may improve image quality.
Collapse
Affiliation(s)
- Kofi Deh
- Radiology, Memorial Sloan Kettering Cancer Center
| | | | - Angela Hijin Park
- Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center
| | - Charles H. Cunningham
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario
- Physical Sciences, Sunnybrook Research Institute, Toronto, Ontario
| | | | - Serge Lyashchenko
- Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center
| | - Shake Ahmmed
- Radiochemistry & Imaging Probes Core (RMIP), Memorial Sloan Kettering Cancer Center
| | | | | | - Hedvig Hricak
- Radiology, Memorial Sloan Kettering Cancer Center
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
| | | | | | - Kayvan R. Keshari
- Radiology, Memorial Sloan Kettering Cancer Center
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
| |
Collapse
|
2
|
Zhang G, Deh K, Park H, Cunningham CH, Bragagnolo ND, Lyashchenko S, Ahmmed S, Leftin A, Coffee E, Kelsen D, Hricak H, Miloushev V, Mayerhoefer M, Keshari KR. Assessment of the Feasibility of Hyperpolarized [1- 13 C]pyruvate Whole-Abdomen MRI using D 2 O Solvation in Humans. J Magn Reson Imaging 2024. [PMID: 38440941 DOI: 10.1002/jmri.29322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 02/14/2024] [Accepted: 02/14/2024] [Indexed: 03/06/2024] Open
Affiliation(s)
- Guannan Zhang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Kofi Deh
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Hijin Park
- Radiochemistry and Molecular Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Charles H Cunningham
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Sunnybrook Research Institute, Toronto, Ontario, Canada
| | | | - Serge Lyashchenko
- Radiochemistry and Molecular Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Shake Ahmmed
- Radiochemistry and Molecular Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | | | - Elizabeth Coffee
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - David Kelsen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Hedvig Hricak
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Vesselin Miloushev
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Marius Mayerhoefer
- Department of Radiology, NYU Grossman School of Medicine, New York City, New York, USA
| | - Kayvan R Keshari
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| |
Collapse
|
3
|
Korde A, Patt M, Selivanova SV, Scott AM, Hesselmann R, Kiss O, Ramamoorthy N, Todde S, Rubow SM, Gwaza L, Lyashchenko S, Andersson J, Hockley B, Kaslival R, Decristoforo C. Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework. EJNMMI Radiopharm Chem 2024; 9:2. [PMID: 38165504 PMCID: PMC10761641 DOI: 10.1186/s41181-023-00230-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Accepted: 12/13/2023] [Indexed: 01/03/2024] Open
Abstract
BACKGROUND Nuclear medicine has made enormous progress in the past decades. However, there are still significant inequalities in patient access among different countries, which could be mitigated by improving access to and availability of radiopharmaceuticals. MAIN BODY This paper summarises major considerations for a suitable pharmaceutical regulatory framework to facilitate patient access to radiopharmaceuticals. These include the distinct characteristics of radiopharmaceuticals which require dedicated regulations, considering the impact of the variable complexity of radiopharmaceutical preparation, personnel requirements, manufacturing practices and quality assurance, regulatory authority interfaces, communication and training, as well as marketing authorisation procedures to ensure availability of radiopharmaceuticals. Finally, domestic and regional supply to ensure patient access via alternative regulatory pathways, including in-house production of radiopharmaceuticals, is described, and an outlook on regulatory challenges faced by new developments, such as the use of alpha emitters, is provided. CONCLUSIONS All these considerations are an outcome of a dedicated Technical Meeting organised by the IAEA in 2023 and represent the views and opinions of experts in the field, not those of any regulatory authorities.
Collapse
Affiliation(s)
- Aruna Korde
- Division of Physical and Chemical Sciences, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Marianne Patt
- Section Radiopharmacy, Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany
| | - Svetlana V Selivanova
- Canadian Nuclear Laboratories, Chalk River, ON, Canada
- Faculty of Pharmacy, Universite Laval, Quebec City, QC, Canada
| | - Andrew M Scott
- Department of Molecular Imaging and Therapy, Austin Health, and Faculty of Medicine, University of Melbourne, Melbourne, Australia
- Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia
| | - Rolf Hesselmann
- Health Protection Directorate, Radiation Protection Division, Section for Research Facilities and Nuclear Medicine, Federal Office of Public Health, Bern, Switzerland
| | - Oliver Kiss
- Department of Targetry, Target Chemistry and Radiopharmacy, Institute for Radipopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | | | - Sergio Todde
- Department of Medicine and Surgery, University of Milano-Bicocca, Tecnomed Foundation, Via Pergolesi, 33, 20900, Monza, Italy
| | - Sietske M Rubow
- Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
| | - Luther Gwaza
- Health Products Policy and Standards Department, World Health Organization, Geneva, Switzerland
| | - Serge Lyashchenko
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Jan Andersson
- Edmonton Radiopharmaceutical Centre, Alberta Health Services, Edmonton, Canada
- Department of Oncology, University of Alberta, Edmonton, Canada
| | - Brian Hockley
- Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, USA
| | - Ravindra Kaslival
- Office of New Drug Products, Office of Pharmaceutical Quality, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
| | - Clemens Decristoforo
- Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
| |
Collapse
|
4
|
Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell 2019; 36:559-573.e7. [PMID: 31668946 PMCID: PMC6996250 DOI: 10.1016/j.ccell.2019.09.007] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 08/20/2019] [Accepted: 09/23/2019] [Indexed: 12/17/2022]
Abstract
Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic tools. We make use of the kinetic selectivity properties of an imaging probe to visualize and measure the epichaperome, a pathologic protein-protein interaction network. We are able to assay and image epichaperome networks in cancer and their engagement by inhibitor in patients' tumors at single-lesion resolution in real time, and demonstrate that quantitative evaluation at the level of individual tumors can be used to optimize dose and schedule selection. We thus provide preclinical and clinical evidence in the use of this theranostic platform for precision medicine targeting of the aberrant properties of protein networks.
Collapse
Affiliation(s)
| | - Komal Jhaveri
- Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Tony Taldone
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Eloisi Caldas-Lopes
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Blesida Punzalan
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Suhasini Joshi
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Alexander Bolaender
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Mohammad M Uddin
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Anna Rodina
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Pengrong Yan
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Anson Ku
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Thomas Ku
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Smit K Shah
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Serge Lyashchenko
- Radiochemistry and Molecular Imaging Probes Core, Sloan Kettering Institute, New York, NY 10065, USA
| | - Eva Burnazi
- Radiochemistry and Molecular Imaging Probes Core, Sloan Kettering Institute, New York, NY 10065, USA
| | - Tai Wang
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Nicolas Lecomte
- Gastrointestinal Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Yelena Janjigian
- Gastrointestinal Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Anas Younes
- Lymphoma Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Connie W Batlevi
- Lymphoma Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Monica L Guzman
- Division of Hematology and Medical Oncology, Leukemia Program, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY 10065, USA
| | - Gail J Roboz
- Division of Hematology and Medical Oncology, Leukemia Program, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY 10065, USA
| | - Jacek Koziorowski
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Pat Zanzonico
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Mary L Alpaugh
- Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Adriana Corben
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Shanu Modi
- Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Larry Norton
- Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Steven M Larson
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program in Molecular Pharmacology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program in Molecular Pharmacology, Sloan Kettering Institute, New York, NY 10065, USA
| | - Gabriela Chiosis
- Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Program in Chemical Biology, Sloan Kettering Institute, New York, NY 10065, USA.
| | - John F Gerecitano
- Lymphoma Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Mark P S Dunphy
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
| |
Collapse
|
5
|
Binderup T, Duivenvoorden R, Fay F, van Leent MMT, Malkus J, Baxter S, Ishino S, Zhao Y, Sanchez-Gaytan B, Teunissen AJP, Frederico YCA, Tang J, Carlucci G, Lyashchenko S, Calcagno C, Karakatsanis N, Soultanidis G, Senders ML, Robson PM, Mani V, Ramachandran S, Lobatto ME, Hutten BA, Granada JF, Reiner T, Swirski FK, Nahrendorf M, Kjaer A, Fisher EA, Fayad ZA, Pérez-Medina C, Mulder WJM. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Sci Transl Med 2019; 11:eaaw7736. [PMID: 31434756 PMCID: PMC7328283 DOI: 10.1126/scitranslmed.aaw7736] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 07/09/2019] [Indexed: 01/01/2023]
Abstract
Nanomedicine research produces hundreds of studies every year, yet very few formulations have been approved for clinical use. This is due in part to a reliance on murine studies, which have limited value in accurately predicting translational efficacy in larger animal models and humans. Here, we report the scale-up of a nanoimmunotherapy from mouse to large rabbit and porcine atherosclerosis models, with an emphasis on the solutions we implemented to overcome production and evaluation challenges. Specifically, we integrated translational imaging readouts within our workflow to both analyze the nanoimmunotherapeutic's in vivo behavior and assess treatment response in larger animals. We observed our nanoimmunotherapeutic's anti-inflammatory efficacy in mice, as well as rabbits and pigs. Nanoimmunotherapy-mediated reduction of inflammation in the large animal models halted plaque progression, supporting the approach's translatability and potential to acutely treat atherosclerosis.
Collapse
Affiliation(s)
- Tina Binderup
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark
| | - Raphaël Duivenvoorden
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 XZ Nijmegen, Netherlands
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Institut Galien Paris Sud, Faculté de Pharmacie, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Mandy M T van Leent
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Joost Malkus
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Samantha Baxter
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Seigo Ishino
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Brenda Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Abraham J P Teunissen
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yohana C A Frederico
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jun Tang
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Giuseppe Carlucci
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Bernard and Irene Schwarz Center for Biomedical Imaging, New York University, New York, NY 10016, USA
| | - Serge Lyashchenko
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Nicolas Karakatsanis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Georgios Soultanidis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, Netherlands
| | - Philip M Robson
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Venkatesh Mani
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Mark E Lobatto
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Radiology, Spaarne Gasthuis, 2035 RC Haarlem, Netherlands
| | - Barbara A Hutten
- Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, 1105 AZ Amsterdam, Netherlands
| | - Juan F Granada
- CRF Skirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY 10962, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Filip K Swirski
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Matthias Nahrendorf
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Andreas Kjaer
- Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark
| | - Edward A Fisher
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY 10016, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, 28029 Madrid, Spain
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, Netherlands
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
| |
Collapse
|
6
|
Kramer K, Kushner B, Modak S, Taskar NP, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, Lewis J, Lyashchenko S, Larson S, Cheung NK. IMMU-05. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Kim Kramer
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Brian Kushner
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Shakeel Modak
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | - Maria Donzelli
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Suzanne Wolden
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Pat Zanzonico
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - John Humm
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Sofia Haque
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | - Ellen Basu
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | - Jason Lewis
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Steven Larson
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | |
Collapse
|
7
|
Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, Lewis J, Lyashchenko S, Larson S, Cheung NK. PDCT-04. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, Lewis J, Lyashchenko S, Larson S, Cheung NK. SCDT-38. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.1119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, Larson SM, Weber WA, Modak S. Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. J Nucl Med 2017; 59:147-153. [PMID: 28705916 PMCID: PMC5750519 DOI: 10.2967/jnumed.117.193169] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Accepted: 06/08/2017] [Indexed: 02/07/2023] Open
Abstract
123I-meta-iodobenzylguanidine (123I-MIBG) imaging is currently a mainstay in the evaluation of many neuroendocrine tumors, especially neuroblastoma. 123I-MIBG imaging has several limitations that can be overcome by the use of a PET agent. 18F-meta-fluorobenzylguanidine (18F-MFBG) is a PET analog of MIBG that may allow for single-day, high-resolution quantitative imaging. We conducted a first-in-human study of 18F-MFBG PET imaging to evaluate the safety, feasibility, pharmacokinetics, and dosimetry of 18F-MFBG in neuroendocrine tumors (NETs). Methods: Ten patients (5 with neuroblastoma and 5 with paraganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of 18F-MFBG intravenously followed by serial whole-body imaging at 0.5-1, 1-2, and 3-4 after injection. Serial blood samples (a total of 6) were also obtained starting at 5 min after injection to as late as 4 h after injection; whole-body distribution and blood clearance data, lesion uptake, and normal-tissue uptake were determined, and radiation-absorbed doses to normal organs were calculated using OLINDA. Results: No side effects were seen in any patient after 18F-MFBG injection. Tracer distribution showed prominent activity in the blood pool, liver, and salivary glands that decreased with time. Mild uptake was seen in the kidneys and spleen, which also decreased with time. Urinary excretion was prominent, with an average of 45% of the administered activity in the bladder by 1 h after injection; whole-body clearance was monoexponential, with a mean biologic half-life of 1.95 h, whereas blood clearance was biexponential, with a mean biologic half-life of 0.3 h (58%) for the rapid α phase and 6.1 h (42%) for the slower β phase. The urinary bladder received the highest radiation dose with a mean absorbed dose of 0.186 ± 0.195 mGy/MBq. The mean total-body dose was 0.011 ± 0.011 mGy/MBq, and the effective dose was 0.023 ± 0.012 mSv/MBq. Both skeletal and soft-tissue lesions were visualized with high contrast. The SUVmax (mean ± SD ) of lesions at 1-2 h after injection was 8.6 ± 9.6. Conclusion: Preliminary data show that 18F-MFBG imaging is safe and has favorable biodistribution and kinetics with good targeting of lesions. PET imaging with 18F-MFBG allows for same-day imaging of NETs. 18F-MFBG appears highly promising for imaging of patients with NETs, especially children with neuroblastoma.
Collapse
Affiliation(s)
- Neeta Pandit-Taskar
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York .,Department of Radiology, Weill Cornell Medical College, New York, New York
| | - Pat Zanzonico
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Kevin D Staton
- Radiochemistry & Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jorge A Carrasquillo
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Radiology, Weill Cornell Medical College, New York, New York
| | - Diane Reidy-Lagunes
- GI Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Serge Lyashchenko
- Radiochemistry & Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.,Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Eva Burnazi
- Radiochemistry & Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.,GI Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Hanwen Zhang
- Radiochemistry & Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jason S Lewis
- Radiochemistry & Molecular Imaging Probe Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.,Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ronald Blasberg
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York; and
| | - Steven M Larson
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Radiology, Weill Cornell Medical College, New York, New York.,Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Wolfgang A Weber
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Shakeel Modak
- Pediatric Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
10
|
Kramer K, Pandit-Taskar N, Humm J, Zanzonico P, Haque S, Dunkel I, Wolden S, Donzelli M, Goldman D, Lewis J, Lyashchenko S, Khakoo Y, Carrasquillo J, Souweidane M, Greenfield J, Lyden D, De Braganca K, Gilheeney S, Larson S, Cheung NK. MEDU-04. A PHASE II STUDY OF RADIOIMMUNOTHERAPY WITH INTRAVENTRICULAR 131I-3F8 FOR MEDULLOBLASTOMA. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S, Ploessl K, Rohle D, Omuro AM, Cross JR, Brennan CW, Weber WA, Holland EC, Mellinghoff IK, Kung HF, Lewis JS, Thompson CB. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci Transl Med 2016; 7:274ra17. [PMID: 25673762 DOI: 10.1126/scitranslmed.aaa1009] [Citation(s) in RCA: 232] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Glucose and glutamine are the two principal nutrients that cancer cells use to proliferate and survive. Many cancers show altered glucose metabolism, which constitutes the basis for in vivo positron emission tomography (PET) imaging with (18)F-fluorodeoxyglucose ((18)F-FDG). However, (18)F-FDG is ineffective in evaluating gliomas because of high background uptake in the brain. Glutamine metabolism is also altered in many cancers, and we demonstrate that PET imaging in vivo with the glutamine analog 4-(18)F-(2S,4R)-fluoroglutamine ((18)F-FGln) shows high uptake in gliomas but low background brain uptake, facilitating clear tumor delineation. Chemo/radiation therapy reduced (18)F-FGln tumor avidity, corresponding with decreased tumor burden. (18)F-FGln uptake was not observed in animals with a permeable blood-brain barrier or neuroinflammation. We translated these findings to human subjects, where (18)F-FGln showed high tumor/background ratios with minimal uptake in the surrounding brain in human glioma patients with progressive disease. These data suggest that (18)F-FGln is avidly taken up by gliomas, can be used to assess metabolic nutrient uptake in gliomas in vivo, and may serve as a valuable tool in the clinical management of gliomas.
Collapse
Affiliation(s)
- Sriram Venneti
- Department of Pathology, University of Michigan, Ann Arbor, MI 41809, USA.
| | - Mark P Dunphy
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA
| | - Hanwen Zhang
- Molecular Pharmacology and Chemistry Program, MSKCC, New York, NY 10065, USA
| | - Kenneth L Pitter
- Cancer Biology and Genetics Program, MSKCC, New York, NY 10065, USA
| | | | - Carl Campos
- Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA
| | - Sean D Carlin
- Radiochemistry and Imaging Sciences Service, Department of Radiology, MSKCC, New York, NY 10065, USA
| | - Gaspare La Rocca
- Cancer Biology and Genetics Program, MSKCC, New York, NY 10065, USA
| | - Serge Lyashchenko
- Radiochemistry and Molecular Imaging Probe Core, MSKCC, New York, NY 10065, USA
| | - Karl Ploessl
- Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Daniel Rohle
- Cancer Biology and Genetics Program, MSKCC, New York, NY 10065, USA. Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA
| | | | - Justin R Cross
- Donald B. and Catherine C. Marron Cancer Metabolism Center, MSKCC, New York, NY 10065, USA
| | - Cameron W Brennan
- Medical Physics, MSKCC, New York, NY 10065, USA. Department of Neurosurgery, MSKCC, New York, NY 10065, USA
| | - Wolfgang A Weber
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA. Molecular Pharmacology and Chemistry Program, MSKCC, New York, NY 10065, USA
| | - Eric C Holland
- Director, Solid Tumor Translational Research, Division of Human Biology, Fred Hutchinson Cancer Research Center, and Alvord Brain Tumor Center, University of Washington, Seattle, WA 98109, USA
| | - Ingo K Mellinghoff
- Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA. Department of Neurology, MSKCC, New York, NY 10065, USA
| | - Hank F Kung
- Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Jason S Lewis
- Molecular Pharmacology and Chemistry Program, MSKCC, New York, NY 10065, USA. Radiochemistry and Imaging Sciences Service, Department of Radiology, MSKCC, New York, NY 10065, USA. Radiochemistry and Molecular Imaging Probe Core, MSKCC, New York, NY 10065, USA.
| | - Craig B Thompson
- Cancer Biology and Genetics Program, MSKCC, New York, NY 10065, USA. Human Oncology and Pathogenesis Program, MSKCC, New York, NY 10065, USA.
| |
Collapse
|
12
|
Venneti S, Dunphy M, Zhang H, Pitter K, Campos C, Carlin S, Lyashchenko S, Ploessl C, Rohle D, Omuro A, Cross J, Brennan C, Weber W, Holland E, Mellinghoff I, Kung H, Lewis J, Thompson C. TM-15 * GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVO. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou278.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol 2013; 191:1439-45. [PMID: 24135437 DOI: 10.1016/j.juro.2013.10.041] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/08/2013] [Indexed: 10/26/2022]
Abstract
PURPOSE In this pilot study we explored the feasibility of (89)Zr labeled J591 monoclonal antibody positron emission tomography of localized prostate cancer. MATERIALS AND METHODS Before scheduled radical prostatectomy 11 patients were injected intravenously with (89)Zr-J591, followed 6 days later by whole body positron emission tomography. Patients underwent surgery the day after imaging. Specimens were imaged by ex vivo micro positron emission tomography and a custom 3 Tesla magnetic resonance scanner coil. Positron emission tomography images and histopathology were correlated. RESULTS Median patient age was 61 years (range 47 to 68), median prostate specific antigen was 5.2 ng/ml (range 3.5 to 12.0) and median biopsy Gleason score of the 11 index lesions was 7 (range 7 to 9). On histopathology 22 lesions were identified. Median lesion size was 5.5 mm (range 2 to 21) and median Gleason score after radical prostatectomy was 7 (range 6 to 9). Eight of 11 index lesions (72.7%) were identified by in vivo positron emission tomography. Lesion identification improved with increasing lesion size for in vivo and ex vivo positron emission tomography (each p <0.0001), and increasing Gleason score (p = 0.14 and 0.01, respectively). Standardized uptake values appeared to correlate with increased Gleason score but not significantly (p = 0.19). CONCLUSIONS To our knowledge this is the first report of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in localized prostate cancer cases. In this setting (89)Zr-J591 bound to tumor foci in situ and positron emission tomography identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. A future, larger clinical validation trial is planned to better define the usefulness of (89)Zr-J591 positron emission tomography for localized prostate cancer.
Collapse
Affiliation(s)
- Joseph R Osborne
- Molecular Imaging and Therapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - David A Green
- Department of Urology, Weill Medical College of Cornell University, New York, New York
| | - Daniel E Spratt
- Department of Radiology, Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Serge Lyashchenko
- Radiochemistry and Imaging Sciences Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Shoaib B Fareedy
- Molecular Imaging and Therapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Brian D Robinson
- Department of Urology, Weill Medical College of Cornell University, New York, New York; Department of Pathology, Weill Medical College of Cornell University, New York, New York
| | - Bradley J Beattie
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Manu Jain
- Department of Urology, Weill Medical College of Cornell University, New York, New York
| | - Jason S Lewis
- Radiochemistry and Imaging Sciences Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Paul Christos
- Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College of Cornell University, New York, New York
| | - Steven M Larson
- Molecular Imaging and Therapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Neil H Bander
- Department of Urology, Weill Medical College of Cornell University, New York, New York
| | - Douglas S Scherr
- Department of Urology, Weill Medical College of Cornell University, New York, New York.
| |
Collapse
|